Concomitant upregulation of all these genes in the osteopontin signaling pathway and in all the NVU cell types may have critical implications for BBB function in ischemic stroke suggesting osteopontin as a therapeutic target in this disease. This evidence concerns the gene SPP1 and ischemic stroke.